US Patent 8,492,416: Brivaracetam Method-of-Use Claims, Expiration, Orange Book Status, and Patent Landscape

US Patent No. 8,492,416 protects the use of brivaracetam, chemically identified as (2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl]butanamide, to treat epilepsy, seizure disorders, and convulsions. The patent is assigned to UCB Pharma S.A. and covers a treatment method rather than the chemical compound, a formulation, a manufacturing process, or a specific dosage regimen.

The patent’s central commercial relevance is its potential to delay US generic brivaracetam use for epilepsy until the patent’s projected expiration in 2029, subject to Orange Book listing, Paragraph IV litigation, settlements, and any later judicial or administrative developments.

What does US Patent 8,492,416 cover?

US 8,492,416 contains two claims:

Claim	Scope
Claim 1	Treating epilepsy, seizure disorders, or convulsions in a mammal by administering a therapeutically effective amount of brivaracetam
Claim 2	The method of claim 1 limited to treatment of epilepsy

The protected active ingredient is brivaracetam, also known as UCB 34714 and marketed in the United States as Briviact. The compound is a high-affinity synaptic vesicle protein 2A ligand used for partial-onset seizures.

The claims do not require:

A specific tablet, capsule, injection, or oral solution
A particular dose or dosing frequency
A specific patient age
Monotherapy or adjunctive therapy
A particular seizure subtype within epilepsy
A specific treatment duration
A defined route of administration
A pharmacokinetic target
A formulation excipient
A manufacturing step

The breadth of the claims comes from the absence of these limitations. Claim 1 covers administration of brivaracetam to a mammal for any of the listed therapeutic purposes, provided the amount is therapeutically effective. Claim 2 is narrower because it removes seizure disorders and convulsions as independent indications and focuses on epilepsy.

What is the chemical scope of Patent 8,492,416?

The claims are directed to one specifically defined stereochemical compound. The designation “(2S)” identifies the stereochemistry at the butanamide carbon, while “(4R)” identifies the stereochemistry in the pyrrolidinone ring.

The chemical structure is:

(2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl]butanamide

This is brivaracetam. The claim does not expressly cover:

Racemic mixtures
The opposite enantiomer
Structurally related racetams
Levetiracetam
Generic SV2A ligands that do not contain the claimed brivaracetam structure
Prodrugs unless administration results in a legally sufficient practice of the claimed method

A generic applicant using the same active ingredient for the claimed indication faces a direct claim issue even if the applicant uses a different formulation, tablet strength, excipient system, or manufacturing route. A different dosage form does not avoid a method claim that does not specify dosage form.

How strong are the claims in US Patent 8,492,416?

The patent has a commercially strong claim structure because the claims are simple, product-specific, and tied to the marketed therapeutic use.

Claim 1 strengths

Claim 1 has several enforcement advantages:

It identifies the exact active ingredient.
It covers three overlapping therapeutic categories: epilepsy, seizure disorders, and convulsions.
It requires no particular dose, route, formulation, or treatment schedule.
It reaches administration to a mammal, which includes human treatment.
It can potentially cover use of oral and intravenous brivaracetam if the other claim elements are met.

The principal vulnerability is the “therapeutically effective amount” limitation. A claimant must establish that the administered quantity is therapeutically effective for the claimed condition. In ordinary commercial use of an approved brivaracetam product for epilepsy, that element is likely to be supported by the FDA-approved labeling and clinical evidence.

Claim 2 strengths

Claim 2 is narrower but commercially important. It expressly covers epilepsy, the principal approved US indication for Briviact. Because the commercial product is used primarily for partial-onset seizures in patients with epilepsy, claim 2 is closely aligned with the approved product.

Its narrower scope may reduce protection against uses outside epilepsy, but it also creates a straightforward infringement theory against a generic label that instructs treatment of epilepsy.

When does US Patent 8,492,416 expire?

The patent issued on July 23, 2013. Its expected expiration is June 11, 2029, based on the underlying US national-stage filing and the 20-year patent-term framework applicable to the family. The exact enforceable term must be assessed against the USPTO patent-term record, including any patent-term adjustment or disclaimer information.

Event	Date or status
Earliest relevant international-family filing	June 11, 2009 national-stage/PCT chronology associated with the US case
US patent issue	July 23, 2013
Patent number	US 8,492,416 B2
Projected expiration	June 11, 2029
Claim type	Method of treatment
Commercial product	Briviact
Active ingredient	Brivaracetam

Patent expiration is separate from FDA regulatory exclusivity. New chemical entity exclusivity for Briviact expired before the projected patent expiration date, allowing ANDA filings subject to listed patent certifications and litigation outcomes.

What is the Orange Book status of Patent 8,492,416?

US 8,492,416 has been associated with Briviact’s US patent protection and is relevant to Orange Book patent analysis for brivaracetam products. The precise current listing, use code, and any changes to the listing should be confirmed against the FDA’s current Approved Drug Products with Therapeutic Equivalence Evaluations database.

For an Orange Book-listed method patent, the key issue is the use code supplied by the innovator. The FDA generally does not decide whether the patent claims are valid or infringed. The listing creates a framework for ANDA applicants to submit one of four certifications:

Paragraph I: no relevant patent information has been submitted
Paragraph II: the patent has expired
Paragraph III: the applicant will wait until patent expiration
Paragraph IV: the patent is invalid, unenforceable, or will not be infringed

A Paragraph IV certification can trigger patent litigation under the Hatch-Waxman Act. If the NDA holder or patent owner files suit within the statutory period, FDA approval of the affected ANDA may be stayed for up to 30 months, subject to statutory exceptions and court developments. [1]

What Paragraph IV challenges affect brivaracetam?

A generic applicant seeking approval for brivaracetam tablets, oral solution, or injection must address applicable Orange Book patents. If US 8,492,416 is listed against the relevant reference product and the proposed labeling includes epilepsy treatment, the applicant may need to submit a Paragraph IV certification or a section viii statement that omits the patented use.

A section viii strategy is more difficult where:

The approved product’s principal indication is the patented use
The proposed generic label necessarily instructs use for epilepsy
The FDA-approved labeling cannot be meaningfully carved out
The product is marketed for the same seizure indication covered by claim 2

A generic could seek a carve-out from a patented method of use if the remaining label supports a noninfringing use. The practical value of that strategy depends on the precise Orange Book use code and the scope of the approved labeling.

Generic launch scenarios

Scenario	Commercial result
Paragraph III certification	Launch delayed until patent expiration, potentially June 2029
Paragraph IV certification with no timely suit	FDA approval may proceed after statutory requirements are met
Paragraph IV certification followed by timely litigation	Potential 30-month approval stay
Successful invalidity or noninfringement challenge	Earlier launch possible
Narrow section viii carve-out	Launch possible for nonpatented uses if FDA accepts the labeling
Settlement agreement	Launch date depends on negotiated terms, authorized generic provisions, and court review

The most valuable generic opportunity would be an earlier launch with an epilepsy label, but that path carries the highest infringement exposure under claim 2.

What other patents protect Briviact and brivaracetam?

US 8,492,416 is one component of a broader brivaracetam patent estate. The landscape generally divides into four categories.

Composition-of-matter patents

Earlier patents covering brivaracetam and related pyrrolidone derivatives protected the active ingredient itself and related compounds. Composition patents are usually more powerful than method patents because they can reach the product regardless of the indication, formulation, or label.

The principal composition protection for brivaracetam was associated with earlier UCB patent families and had an earlier expiration profile than the 2029 method patent. Once composition protection expires, a generic may manufacture and sell the molecule, subject to surviving formulation, use, and manufacturing patents.

Method-of-use patents

US 8,492,416 is a method-of-use patent. Its commercial value depends on whether generic labeling or actual commercial conduct instructs or encourages the patented epilepsy use.

Method patents can remain commercially relevant after compound patents expire, particularly where the approved product has one dominant indication. Their enforcement is more fact-dependent than composition patents because the patentee must connect the accused product’s labeling, marketing, or use to the claimed treatment method.

Formulation and dosage-form patents

Briviact is marketed in multiple dosage forms, including tablets, oral solution, and injection. Formulation patents may cover:

Specific oral dosage forms
Liquid compositions
Stability-enhancing excipients
Injectable formulations
Concentration ranges
Salt or solid-state properties
Packaging or storage conditions

A generic can sometimes avoid a formulation patent by using a different excipient system or dosage form. That strategy does not necessarily avoid US 8,492,416 because the method claims do not require a formulation limitation.

Manufacturing and process patents

Process patents may cover preparation of brivaracetam, chiral intermediates, resolution methods, crystallization, purification, or impurity control. They can create manufacturing barriers even after product patents expire, particularly where the commercial process depends on a protected stereoselective route.

A process patent generally does not block all manufacture of brivaracetam. Its effect depends on whether the generic producer uses the claimed process in the United States or imports product made by that process under applicable patent-law provisions.

Does biosimilar risk apply to Briviact?

No. Brivaracetam is a chemically synthesized small-molecule drug, not a biologic subject to the biosimilar pathway under the Public Health Service Act. The relevant competitive pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The principal regulatory competition risks are therefore:

ANDA filings
Paragraph IV certifications
Section viii labeling carve-outs
Authorized generic supply
Formulation differentiation
Patent litigation and settlement

Biosimilar interchangeability, reference-product exclusivity under the biologics framework, and biologic patent dance procedures do not apply.

Which companies are likely to challenge Briviact patent protection?

Generic companies that have historically filed ANDAs for antiepileptic medicines are the most likely potential challengers. Relevant market participants may include Teva Pharmaceuticals, Amneal Pharmaceuticals, Lupin, Aurobindo, Dr. Reddy’s Laboratories, Zydus, Sun Pharma, and other ANDA sponsors.

The existence of an ANDA filing, Paragraph IV notice letter, or litigation should not be inferred solely from a company’s presence in the antiepileptic market. A definitive competitor assessment requires the FDA Orange Book, district-court docket records, ANDA litigation complaints, and any settlement filings.

What litigation and settlement issues matter?

For US 8,492,416, the critical litigation questions are:

Whether the patent is listed for the proposed generic product and indication.
Whether the ANDA applicant made a Paragraph IV certification.
Whether UCB or the NDA holder filed suit within the statutory period.
Whether the court found the claims valid, enforceable, and infringed.
Whether a settlement established an agreed launch date.
Whether the settlement included an authorized generic or supply arrangement.
Whether the generic label encourages the patented epilepsy use.

A method-of-use case will often focus on the proposed label, promotional materials, product distribution, and whether the generic has a realistic noninfringing use. The absence of a specific dosage limitation makes dose-based noninfringement arguments less useful against the literal text of these claims.

How does US 8,492,416 compare with brivaracetam composition patents?

Issue	Composition patent	US 8,492,416
Protected subject matter	Brivaracetam molecule or related compounds	Treatment method using brivaracetam
Scope	Can cover product regardless of indication	Requires claimed therapeutic administration
Formulation dependence	Usually none	None stated
Label dependence	Lower	Higher
Typical expiration	Earlier brivaracetam family term	Projected June 11, 2029
Generic design-around	Difficult before expiration	Possible through label carve-out or noninfringing use
Litigation focus	Product manufacture, sale, importation	Use, labeling, inducement, and indication

The method patent can extend practical commercial protection beyond earlier compound-patent expiry. Its strength is highest when the patented indication is the product’s principal or unavoidable use.

What is the commercial exposure from this patent?

Briviact generated substantial US revenue for UCB, with the United States representing a major portion of the product’s global commercial base. The patent’s economic value depends on the timing of generic approval and launch rather than on the patent’s nominal expiration date alone.

An earlier generic launch could produce:

Rapid price erosion
Payer-driven substitution
Loss of branded prescription volume
Reduced oral and injectable sales
Pressure on hospital and specialty-pharmacy contracts

A delayed launch until 2029 would preserve additional branded revenue, although the magnitude depends on competing antiepileptic therapies, generic levetiracetam pricing, payer restrictions, and the number of generic entrants.

Key Takeaways

US 8,492,416 covers treatment of epilepsy, seizure disorders, and convulsions with brivaracetam.
Claim 2 specifically targets epilepsy, Briviact’s core approved therapeutic use.
The claims do not require a specific dose, route, dosage form, formulation, or treatment duration.
The patent is a method-of-use patent, not a composition-of-matter patent.
Its projected expiration is June 11, 2029.
Generic applicants face Paragraph IV and section viii strategy issues if the patent is listed for the relevant Briviact product.
Brivaracetam is a small molecule, so biosimilar competition does not apply.
Earlier composition patents and later formulation, dosage-form, and process patents must be analyzed separately.
The most consequential generic risk is an ANDA carrying an epilepsy indication, because that label maps directly onto claim 2.
A noninfringing label carve-out may be legally available only if the FDA-approved use code and remaining indications permit one.

Frequently Asked Questions

Is US Patent 8,492,416 a patent on Briviact itself?

No. It is a method-of-treatment patent covering administration of brivaracetam for epilepsy, seizure disorders, and convulsions. Earlier patents provided composition-related protection for brivaracetam.

Can a generic sell brivaracetam after composition patents expire?

Potentially, but surviving method-of-use, formulation, process, and regulatory barriers must be addressed. A generic product labeled for epilepsy may face the claims of US 8,492,416.

Does changing the Briviact dosage form avoid Patent 8,492,416?

Not necessarily. The claims do not require a tablet, capsule, oral solution, or injection. Changing dosage form alone does not remove the claimed brivaracetam treatment method.

Can a generic use a section viii statement against this patent?

Possibly. The strategy depends on the Orange Book use code and whether the generic can omit the patented epilepsy use while retaining an FDA-approvable noninfringing indication.

Is brivaracetam subject to biosimilar litigation?

No. Brivaracetam is a chemically synthesized small molecule. Competition proceeds through the ANDA and Hatch-Waxman framework rather than the biosimilar pathway.

References

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
United States Patent and Trademark Office. (2013). U.S. Patent No. 8,492,416 B2: Use of brivaracetam for treating epilepsy.
U.S. Food and Drug Administration. (2016). Briviact (brivaracetam) prescribing information. UCB, Inc.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/drugs
U.S. Code. (2024). 35 U.S.C. §§ 154, 271, and 282; 21 U.S.C. § 355.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0004297.8	Feb 23, 2000

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1265862	⤷ Start Trial	PA2016013	Lithuania	⤷ Start Trial
European Patent Office	1452524	⤷ Start Trial	300815	Netherlands	⤷ Start Trial
European Patent Office	1452524	⤷ Start Trial	CA 2016 00013	Denmark	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,492,416

Summary for Patent: 8,492,416